Black Diamond Therapeutics, Inc. BDTX

BDTX Company Overview

Black Diamond Therapeutics, Inc. is a clinical-stage precision oncology company focused on developing small-molecule therapies for patients with genetically defined cancers. The company operates within the biotechnology and oncology therapeutics industries, with a primary emphasis on targeting oncogenic mutations that are difficult to treat using existing precision medicines. Its core scientific approach is centered on developing “MasterKey” therapies designed to address broad families of tumor mutations rather than single mutation variants. Black Diamond Therapeutics is publicly traded on Nasdaq under the ticker BDTX.

The company’s primary revenue sources historically have consisted of collaboration revenue, research funding, and capital raised through equity offerings, as it remains in the clinical development stage and does not currently market approved commercial products. Its lead programs have focused on epidermal growth factor receptor (EGFR)-driven cancers and other mutation-defined solid tumors. Black Diamond Therapeutics was founded in 2014 and evolved from early academic and computational oncology research into a clinically focused biotechnology company advancing targeted cancer therapies for patients with limited treatment options.